A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

British Journal of Haematology

Volumn 127, Issue 2, 2004, Pages 165-172

  Jagannath, Sundar ^a,n   Barlogie, B ^b   Berenson, J ^c   Siegel, D ^d   Irwin, D ^e   Richardson, P G ^f   Niesvizky, R ^g   Alexanian, R ^h   Limentani, S A ⁱ   Alsina, M ^j   Adams, J ^k   Kauffman, M ^l   Esseltine, D L ^m   Schenkein, D P ^m   Anderson, K C ^f  

^a ST VINCENT S HOSPITAL   (United States)

^b UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^c INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^d HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^e Alta Bates Comprehensive Cancer Center   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ Carolinas Hematology Oncology Associates   (United States)

^j H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^k Infinity Pharmaceuticals Inc   (United States)

^l Predix Pharmaceuticals   (United States)

^m MILLENNIUM PHARMACEUTICALS INC   (United States)

ⁿ ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

more..

Author keywords

Bortezomib; Dexamethasone; Myeloma; Refractory; Relapsed

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; PROTEASOME INHIBITOR;

ADULT; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; FATIGUE; FEVER; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPONATREMIA; INSOMNIA; LIMB PAIN; LYMPHOCYTOPENIA; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; PYRAZINES; RECURRENCE; SURVIVAL RATE;

EID: 5644250621     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05188.x     Document Type: Article

References (16)

1. Adams, J., Behnke, M., Chen, S., Cruickshank, A.A., Dick, L.R., Grenier, L., Klunder, J.M., Ma, Y.T., Plamondon, L. & Stein, R.L. (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorganic and Medicinal Chemistry Letters, 8, 333-338.
2. Aghajanian, C., Soignet, S., Dizon, D.S., Pien, C.S., Adams, J., Elliott, P.J., Sabbatini, P., Miller, V., Hensley, M.L., Pezzulli, S., Canales, C., Daud, A. & Spriggs, D.R. (2002) A phase 1 trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clinical Cancer Research, 8, 2505-2511.
3. Alexanian, R. & Dimopoulos, M. (1994) The treatment of multiple myeloma. New England Journal of Medicine, 330, 484-489.
4. Bladé, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115-1123.
5. Desterro, J.M., Rodriguez, M.S. & Hay, R.T. (2000) Regulation of transcription factors by protein degradation. Cellular and Molecular Life Sciences, 57, 1207-1219.
6. Dulic, V., Kaufmann, W.K., Wilson, S.J., Tlsty, T.D., Lees, E., Harper, J.W., Elledge, S.J. & Reed, S.I. (1994) p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell, 76, 1013-1023.
7. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. & Anderson, K.C. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 3071-3076.
8. King, R.W., Deshaies, R.J., Peters, J.M. & Kirschner, M.W. (1996) How proteolysis drives the cell cycle. Science, 274, 1652-1659.
9. LeBlanc, R., Catley, L.P., Hideshima, T., Lentzsch, S., Mitsiades, C.S., Mitsiades, N., Neuberg, D., Goloubeva, O., Pien, C.S., Adams, J., Gupta, D., Richardson, P.G., Munshi, N.C. & Anderson, K.C. (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Research, 62, 4996-5000.
10. Orlowski, R.Z. (1999) The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death and Differentiation, 6, 303-313.
11. Orlowski, R.Z., Stinchcombe, T.E., Mitchell, B.S., Shea, T.C., Baldwin, A.S., Stahl, S., Adams, J., Esseltine, D.L., Elliott, P.J., Pien, C.S., Guerciolini, R., Anderson, J.K., Depcik-Smith, N.D., Bhagat, R., Lehman, M.J., Novick, S.C., O'Connor, O.A. & Soignet, S.L. (2002) Phase 1 trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. Journal of Clinical Oncology, 20, 4420-4427.
12. Rajkumar, S.V., Gertz, M.A., Kyle, R.A. & Greipp, P.R. (2002) Current therapy for multiple myeloma. Mayo Clinic Proceedings, 77, 813-822.
13. Read, M.A., Neish, A.S., Luscinskas, F.W., Palombella, V.J., Maniatis, T. & Collins, T. (1995) The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity, 2, 493-506.
14. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. Srkalovic & Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 2609-2617.
15. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. & Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565-1571.
16. Strasser, K. & Ludwig, H. (2002) Thalidomide treatment in multiple myeloma. Blood Reviews, 16, 207-215.